Diabetes – Medical Marijuana Research Overview

The following information is presented for educational purposes only. Medical Marijuana Inc. provides this information to provide an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred.

Diabetes mellitus is a metabolic disease that prevents the body from properly utilizing glucose. Studies have shown marijuana reduces the risk of diabetes, can help treat diabetes once its developed, and assists in the management of pain associated with the disease.

Overview of Diabetes

Diabetes mellitus, also commonly simply referred to as diabetes, is a group of diseases that influences how the body uses glucose. Glucose, or blood sugar, is an important source of fuel for the body’s cells and is the main source of energy for the brain. In diabetes, there is too much glucose in the bloodstream. Glucose builds up because of an issue with insulin, a hormone made by the pancreas that allows your body to process and use glucose.

There are two types of diabetes. Type 1 diabetes, or insulin-dependent diabetes, commonly affects children and teenagers and occurs when the pancreas doesn’t produce enough insulin. Type 2 diabetes, which accounts for 90 to 95% of all diabetes cases, occurs when the pancreas doesn’t produce enough insulin or the body’s cells fail to respond to insulin properly.

Having too much glucose in the blood can lead to serious health problems, including cardiovascular disease, nerve damage, kidney damage, eye damage, foot damage, skin conditions and hearing impairment.

The symptoms associated with diabetes include increased thirst and frequent urination, unexplained weight loss, fatigue, extreme hunger, irritability, blurred vision, presence of ketones in urine, dry and itchy skin, and frequent infections.

The case of type 1 diabetes continues to be unknown. The body’s immune system accidentally attacks and destroys the cells within the pancreas that produce insulin. Type 2 diabetes is linked to being overweight and a lack of exercise.

Treatments for diabetes commonly include the encouragement of healthy eating and regular exercise to lower body weight. In addition, regularly monitoring blood sugar is important for those with type 1 and type 2 diabetes. Insulin injections may be needed to adjust blood glucose levels.

Findings: Effects of Cannabis on Diabetes

Studies indicate that cannabis may be beneficial for treating diabetes. Cannabinoids have also shown to elicit anti-inflammatory effects that effectively treat Type 1 diabetes in mice (Acharya, et al., 2017).

Other researchers found that those who consumed cannabis in the past year were more likely to possess a lower body mass index, lower fasting insulin and lower insulin resistance compared to non-users (Ngueta, Belanger, Laouan-Sidi & Lucas, 2015). Cannabinoids have also shown they can play a role in the regulation of glucose metabolism, suggesting that they’re beneficial for regulating fat tissue in humans that are obese (Pagano, et al., 2007).

Cannabinoids act upon the cannabinoid receptors (CB1 and CB2) of the endocannabinoid system, which stimulates anti-inflammatory and analgesic responses (Bermudez-Silva, et al., 2008) (Di Marzo, 2008) . Because of cannabis’ anti-inflammatory effects, researchers have concluded that it can serve as a viable therapeutic option in the treatment of inflammatory diseases, like diabetes (Croxford & Yamamura, 2005). An animal study found that action on the CB1 receptor decreased non-fasting plasma glucose, improved glycemic response to glucose and enhanced insulin sensitivity (Irwin, Hunter, Frizzell & Flatt, 2008). When combined with a hypocaloric diet, blocking the CB1 receptor over one year was shown to cause a significant decrease in bodyweight and waist circumference and cause an improvement in cardiovascular risk factors (Van Gaal, et al., 2005). Another study found cannabinoids to be effective at reducing β-cell destruction, which leads to insulin deficiency and cause of type 1 diabetes (Kim, et al., 2016).

Cannabis may also assist in the management of pain associated with diabetes. In an animal study, administering cannabinoids in mice reduced diabetic-related tactile allodynia or pain resulting from a non-injurious stimulus to the skin (Dogrul, et al., 2004).

States That Have Approved Medical Marijuana for Diabetes

No states have specifically approved medical marijuana for the treatment of diabetes. However, a number of other states will consider allowing medical marijuana to be used for the treatment of diabetes with the recommendation from a physician. These states include: California (any debilitating illness where the medical use of marijuana has been recommended by a physician), Connecticut (other medical conditions may be approved by the Department of Consumer Protection), Massachusetts (other conditions as determined in writing by a qualifying patient’s physician), Nevada (other conditions subject to approval), Oregon (other conditions subject to approval), Rhode Island (other conditions subject to approval), and Washington (any “terminal or debilitating condition”).

In Washington D.C., any condition can be approved for medical marijuana as long as a DC-licensed physician recommends the treatment.

In addition, Illinois has approved medical marijuana for the treatment of diabetic neuropathy, which can occur in those with diabetes. Several states have approved medical marijuana specifically to treat “chronic pain.” These states include: Alaska, Arizona, California, Colorado, Delaware, Hawaii, Maine, Maryland, Michigan, Montana, New Mexico, Ohio, Oregon, Pennsylvania, Rhode Island, Vermont, and West Virginia. The states of Nevada, New Hampshire, North Dakota, Montana, Ohio and Vermont allow medical marijuana to treat “severe pain.” The states of Arkansas, Minnesota, Ohio, Pennsylvania, Washington, and West Virginia have approved cannabis for the treatment of “intractable pain.”

Recent Studies on Cannabis’ Effect on Diabetes


  1. Acharya, N., Penukonda, S., Shcheglova, T., Hagymasi, A.T., Basu, S., and Srivastava, P.K. (2017, March 27). Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proceedings of the National Academy of Sciences of the United States, 114(19), 5005-5010. Retrieved from http://www.pnas.org/content/114/19/5005.full.
  2. Bermudez-Silva, F.J., Suarez, J., Baixeras, E., Cobo, N., Bautista, D., Cuesta-Munoz, A.L., Fuentes, E., Juan-Pico, P., Castro, M.J., Milman, G., MEchoulam, R., Nadal, A., and Rodriguez de Fonseca, F. (2008, March). Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia, 51(3), 476-87. Retrieved from http://link.springer.com/article/10.1007%2Fs00125-007-0890-y.
  3. Croxford, J.L., and Yamamura, T. (2005, September). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? Journal of Neuroimmunology, 166(1-2), 3-18. Retrieved from http://www.jni-journal.com/article/S0165-5728(05)00160-8/fulltext.
  4. Diabetes. (2014, May). FamilyDoctor.org. Retrieved from http://familydoctor.org/familydoctor/en/diseases-conditions/diabetes.printerview.all.html.
  5. Diabetes. (2014, July 31). Mayo Clinic. Retrieved from http://www.mayoclinic.org/diseases-conditions/diabetes/basics/definition/con-20033091.
  6. Di Marzo, V. (2008, August). The endocannabinoid system in obesity and type 2 diabetes. Diabetologia, 51(8), 1356-67. Retrieved from http://link.springer.com/article/10.1007%2Fs00125-008-1048-2.
  7. Dogrul, A., Gul, H., Yildiz, O., Bilgin, F., and Guzeldemir, M.E. (2004, September 16). Cannabinoids blocks tactile allodynia in diabetic mice without attentuation of its antinociceptivee effect. Neuroscience Letters, 368(1), 82-6. Retrieved from http://www.sciencedirect.com/science/article/pii/S0304394004007980.
  8. Irwin, N., Hunter, K., Frizzell, N., and Flatt, P.R. (2008, February 26). Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. European Journal of Pharmacology, 581(1-2), 226-33. Retrieved from http://www.sciencedirect.com/science/article/pii/S0014299907013209.
  9. Kim, J., Lee, K.J., Kim, J.S., Rho, J.G., Shin, J.J., Song, W.K., Lee, E.K., Egan, J.M., and Kim, W. (2016). Cannabinoids Regulate Bcl-2 and Cyclin D2 Expression in Pancreatic β Cells. PLoS ONE, 11(3), e0150981. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788443/.
  10. Ngueta, G., Belanger, R.E., Laouan-Sidi, E.A., and Lucas, M. (2015, February). Cannabis use in relation to obesity and insulin resistance in the inuit population. Obesity, 23(2), 290-295. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/oby.20973/full.
  11. Pagano, C., Pilon, C., Calcagno, A., Urbanet, R., Rossato, M., Milan, G., Bianchi, K., Rizzuto, R., Bernante, P., Federspil, G., and Vettor, R. (2007, December). The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. The Journal of Clinical Endocrinology & Metabolism, 92(12), 4810-4819. Retrieved from https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2007-0768.
  12. Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., Rossner, S., and RIO-Europe Study Group. (2005, April). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, (365)9468, 1389-97. Retrieved from http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)66374-X/fulltext.


  • October 9, 2015
  • Eve Ripley